Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Visx

This article was originally published in The Gray Sheet

Executive Summary

Financier Carl Icahn declares intent to nominate Keith Meister to the ophthalmic firm's board of directors. Icahn, who owns 11.6% of the company, had scrapped plans to elect a rival slate of directors in March. A hostile takeover was initially proposed in April 2001 (1"The Gray Sheet" Nov. 26, 2001, p. 30)...

You may also be interested in...



Icahn Renews Effort To Replace Visx Board At Next Shareholder Meeting

Financier Carl Icahn appears to have abandoned his $32 a share cash tender offer for Visx in favor of electing a rival slate of directors to the firm's board, a strategy that in the past has failed

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017609

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel